StockNews.AI
ALT
StockNews.AI
49 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

1. Pomerantz LLP is investigating claims against Altimmune for possible securities fraud. 2. ALT's stock fell 53.18% after reported trial results deemed statistically insignificant. 3. Altimmune described trial results as 'positive', but key endpoints were not significant. 4. Investors are urged to contact legal representatives for potential class action involvement.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The significant drop in ALT's stock price indicates market skepticism due to trial results. Historical context shows that similar cases of clinical disappointment typically lead to further declines in biotech stocks.

How important is it?

The article indicates serious legal implications and adverse market reactions which can lead to ongoing volatility for ALT.

Why Short Term?

The immediate investigation can cause further selling pressure, impacting ALT in the near term. Previous biotech companies faced declines following similar investigations.

Related Companies

PFENVAXMRNA
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Altimmune, Inc.  (“Altimmune” or the “Company”) (NASDAQ: ALT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 26, 2025, Altimmune issued a press release announcing “topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).”  Although Altimmune described the results as “positive,” the press release reported that “[t]he effects on fibrosis improvement without worsening of MASH in an ITT analysis”—a key efficacy endpoint—“were 31.8% and 34.5% for pemvidutide 1.2 mg and 1.8 mg, respectively compared with 25.9% for placebo (differences not statistically significant).”  On this news, Altimmune’s stock price fell $4.10 per share, or 53.18%, to close at $3.61 per share on June 26, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com 646-581-9980 ext. 7980

Related News